{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T12:19:40Z","timestamp":1783426780561,"version":"3.54.6"},"reference-count":25,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T00:00:00Z","timestamp":1744675200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2025,4,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>This study describes baseline and clinical characteristics, treatment patterns, survival, and safety outcomes of patients with acute myeloid leukemia (AML) who received oral azacitidine (oral\u2010AZA) maintenance therapy in Canada following its approval in 2021.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective, observational medical record review was conducted of patients with AML in remission after induction therapy and who initiated treatment with oral\u2010AZA between March 2021 and July 2023 in Canada. Real\u2010world relapse\u2010free survival and overall survival outcomes were estimated using Kaplan\u2013Meier methodology.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Data from 119 patients were analyzed. The median age at oral\u2010AZA initiation was 62.5 years. Most patients had favorable (39.5%) or intermediate (39.5%) genetic risk per the 2017\/2022 European LeukemiaNet classification. Nearly all patients (99.2%) received cytarabine\u2010based induction regimens. A total of 55.5% of patients received consolidation therapy, with a median of two cycles. After a median follow\u2010up of 9.4 months, 68.1% of all patients were still receiving oral\u2010AZA at last follow\u2010up. After oral\u2010AZA treatment, 21.0% of patients relapsed. Rates of real\u2010world relapse\u2010free survival and overall survival at 12 months from oral\u2010AZA initiation were 66.9% and 74.5%, respectively. During oral\u2010AZA treatment, 67.2% of patients experienced \u22651 adverse event. Concomitant antiemetic treatment was received by 78.2% of patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>These findings provide real\u2010world evidence further supporting the use of oral\u2010AZA as a standard\u2010of\u2010care maintenance therapy in current routine clinical practice for patients with AML in remission who do not receive hematopoietic stem cell transplantation. These results may inform a broader clinical audience because of the inclusion of patients with diverse demographic and clinical characteristics.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.35845","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T13:48:11Z","timestamp":1744724891000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Real\u2010world treatment patterns and outcomes with oral azacitidine maintenance therapy in patients with acute myeloid leukemia"],"prefix":"10.1002","volume":"131","author":[{"given":"Brian","family":"Leber","sequence":"first","affiliation":[{"name":"McMaster University  Hamilton Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcia T.","family":"Ruiz","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb  Princeton New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hany","family":"Elgendy","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb  Princeton New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippa","family":"Pettersson","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb  Princeton New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Prebet","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb  Princeton New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos E.","family":"Vigil","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb  Princeton New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohan C.","family":"Parikh","sequence":"additional","affiliation":[{"name":"RTI Health Solutions  Research Triangle Park North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddhi","family":"Korgaonkar","sequence":"additional","affiliation":[{"name":"RTI Health Solutions  Research Triangle Park North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fareedat","family":"Bello","sequence":"additional","affiliation":[{"name":"RTI Health Solutions  Research Triangle Park North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith L.","family":"Davis","sequence":"additional","affiliation":[{"name":"RTI Health Solutions  Research Triangle Park North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lona","family":"Gaugler","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb  Princeton New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Strocchia","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb  Princeton New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Sieluk","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb  Princeton New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeran","family":"Li","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb  Princeton New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre C.","family":"Schuh","sequence":"additional","affiliation":[{"name":"UHN Research  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,4,15]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26822"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40164\u2010020\u201000170\u20106"},{"key":"e_1_2_10_4_1","unstructured":"Canadian Cancer Society.Survival statistics for acute myeloid leukemia.2024. Updated February 2022; Accessed May 8 2024.https:\/\/cancer.ca\/en\/cancer\u2010information\/cancer\u2010types\/acute\u2010myeloid\u2010leukemia\u2010aml\/prognosis\u2010and\u2010survival\/survival\u2010statistics"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2004444"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.3727\/096504020x15965357399750"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29090491"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/1828223"},{"key":"e_1_2_10_9_1","unstructured":"ONUREG Product Monograph.2024. Updated February 29 2024; Accessed May 16 2024.https:\/\/pdf.hres.ca\/dpd_pm\/00074778.PDF"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102009\u201007\u2010235358"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00067"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021013626"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102005\u201005\u20102004"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102016\u201008\u2010733196"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016867"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102016\u201006\u2010721662"},{"key":"e_1_2_10_17_1","article-title":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Acute Myeloid Leukemia","volume":"2","author":"NCCN","year":"2025","journal-title":"National Comprehensive Cancer Network"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016293"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02619"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.Ccr\u201018\u20102990"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.2147\/ott.S150807"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614359"},{"key":"e_1_2_10_23_1","unstructured":"Food and Drug Administration.FDA approves new combination treatment for acute myeloid leukemia.2018. Updated March 28 2018.https:\/\/www.fda.gov\/news\u2010events\/press\u2010announcements\/fda\u2010approves\u2010new\u2010combination\u2010treatment\u2010acute\u2010myeloid\u2010leukemia"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598\u2010024\u201057295\u20105"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102023\u2010173442"},{"key":"e_1_2_10_26_1","unstructured":"ClinicalTrials.gov NCT05287568.CC\u2010486 and venetoclax for acute myeloid leukemia.2022. Accessed 26 June 2024.https:\/\/clinicaltrials.gov\/study\/NCT05287568"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.35845","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T12:15:07Z","timestamp":1760271307000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.35845"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,15]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,4,15]]}},"alternative-id":["10.1002\/cncr.35845"],"URL":"https:\/\/doi.org\/10.1002\/cncr.35845","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,15]]},"assertion":[{"value":"2024-12-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e35845"}}